Phuturdex › Drugs › Octreotide Acetate
Drugs in development · updated 11 November 2026
Octreotide Acetate: clinical trials and development status
Other names and codes: CAM2029, Oczyesa, Mycapssa
As of 11 November 2026 Octreotide Acetate is in 6 active clinical trials (recruiting or ongoing, phases I–III) for 13 diseases. The most advanced phase is III.
Authorisation
- EU yes, since 30 Jun 2025 (EMA)
- Italy yes, Octreotide Sun, Octreotide Teva (AIFA register)
- Germany yes (EU authorisation)
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Autosomal dominant polycystic kidney | II–III | 1 | NCT05281328 |
| Gastro-enteropancreatic neuroendocrine tumor | III | 1 | NCT05050942 |
| Neuroendocrine tumor | III | 1 | NCT00569127 |
| Polycystic liver disease | II–III | 1 | NCT05281328 |
| Postural orthostatic tachycardia syndrome | I–II | 1 | NCT00262470 |
| Sinus tachycardia | I–II | 1 | NCT00262470 |
| Tachycardia | I–II | 1 | NCT00262470 |
| Diabetes | I | 1 | NCT06558422 |
| Hyperinsulinism | I | 1 | NCT06558422 |
| Insulin resistance | I | 1 | NCT06558422 |
| Non-alcoholic Fatty Liver Disease | I | 1 | NCT06558422 |
| Obesity | I | 1 | NCT06558422 |
| Prediabetes | I | 1 | NCT06558422 |
Sites in Europe
63 sites of the active trials in 8 European countries, 0 recruiting.
- Spain15
- Italy11
- Germany10
- France8
- Belgium6
- Netherlands5
- Hungary4
- Romania4
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
Everything on Octreotide Acetate
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.